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http://dx.doi.org/10.1016/j.ccr.2013.02.018SUMMARYThe fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling network plays an
important role in cell growth, survival, differentiation, and angiogenesis. Deregulation of FGFR signaling
can lead to cancer development. Here, we report an FGFR inhibitor, SSR128129E (SSR), that binds to the
extracellular part of the receptor. SSR does not compete with FGF for binding to FGFR but inhibits FGF-
induced signaling linked to FGFR internalization in an allostericmanner, as shown by crystallography studies,
nuclear magnetic resonance, Fourier transform infrared spectroscopy, molecular dynamics simulations, free
energy calculations, structure-activity relationship analysis, and FGFR mutagenesis. Overall, SSR is a small
molecule allosteric inhibitor of FGF/FGFR signaling, acting via binding to the extracellular part of the FGFR.INTRODUCTION
Receptor tyrosine kinases (RTKs) constitute a major class of
drug targets (Overington et al., 2006). Most efforts have been
invested in developing agents that orthosterically compete for
binding between RTKs with their endogenous ligands, such as
antibodies recognizing growth factors or their receptors or smallSignificance
FGF receptors (FGFRs) belong to the receptor tyrosine kina
numerous (patho-)physiological processes and a key target fo
domains of RTKs are traditionally antibodies, but small chemi
inhibiting RTK signaling, have not been described yet. This s
of FGFRs and investigated its allosteric mechanisms. Besides
further development of additional small, extracellularly acting
receptors.molecules that inhibit their tyrosine kinase (TK) activity (Gasparini
et al., 2005; Zhang et al., 2009). Only a few drugs that interact
with allosteric sites have been developed for ion channels and
G protein-coupled receptors (Christopoulos, 2002; Conn et al.,
2009) and kinases (Zhang et al., 2009). In contrast to orthosteric
inhibitors, advantages of allosteric drugs include specificity and
safety (Christopoulos, 2002).se (RTK) superfamily, which is of immense importance for
r drug development. Most drugs targeting the extracellular
cal compounds, acting extracellularly, which are capable of
tudy identified an extracellularly binding allosteric inhibitor
therapeutic advantages of allosteric drugs, our data warrant
, allosteric molecules for targeting this important class of
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Figure 1. Chemical Structure, Cellular Effects, and NMR of SSR
(A) Chemical structure of SSR128129E (SSR).
(B) Apoptosis assay to study SSR’s potency of inhibiting EC survival (mean ± SEM; n = 3).
(C) FGFR2-kinase assay to compare the effect of SSR and SU5402 (mean ± SEM; n = 3). The asterisk indicates that p < 0.05. NS, not significant.
(D) 1H and STD-NMR spectra of SSR in the presence of FGFR1 and FGFR4 as compared to the 1H-NMR spectrum of SSR alone.
See also Figure S1 and Table S1.
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Mechanism of SSR to Allosterically Block FGFRsBy using a high-throughput scintillation proximity binding
assay (SPA), we identified compounds that inhibited binding of
125I-FGF2 to the extracellular domain of FGFR1, comprising three
immunoglobulin-like domains D1–D3 coupled to an Fc-fragment
(FGFR1-D1D2D3/Fc). After screening >105 compounds and
chemical optimization, one compound (SSR128129E, abbrevi-
ated as ‘‘SSR’’) inhibited 125I-FGF2 binding with mM affinity,
although this effect was not saturated (Bono et al., 2013). These
findings suggested amodulation in fibroblast growth factor (FGF)
binding but not necessarily binding competition. Further, SSR
reduced FGFR phosphorylation but did not cross the plasma
membrane, while inhibiting cell proliferation at nM potency. The
discrepancy of the inhibition constants between the SPA results
and proliferation assay led us to investigate the molecular mech-
anisms of SSR. Pharmacological experiments showed that this
compound inhibited FGF receptor (FGFR) signaling via an allo-
steric mechanism (Bono et al., 2013), which we studied in more
molecular detail here.
RESULTS
SSR128129E Inhibits FGFR andBinds to Its Extracellular
Domain
We identified SSR128129E, referred to as ‘‘SSR’’ (Figure 1A),
which inhibited the binding of 125I-FGF2 to the extracellular
domain (ECD) of FGFR1 at mM concentrations in a SPA assay
(Bono et al., 2013). SSR dose-dependently inhibited the survival
of endothelial cells (ECs) (IC50 < 30 nM; Figure 1B).
Since SSR’s effects on FGFR signaling did not result from an
inhibition of FGF binding to FGFRs (Bono et al., 2013), impaired
dimerization of FGFRs or FGF ligands (Figures S1A and S1B490 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.available online), or TK inhibition (Figure 1C), we used satura-
tion transfer difference (STD)-nuclear magnetic resonance
(NMR) to analyze if, after FGFR irradiation, the NMR signal (satu-
ration) would spread to SSR, which would indicate that SSR
interacts with FGF. However, SSR did not bind FGF1 or FGF2
(Figure S1C).
We assessed if SSR bound FGFR-ECD, in which D2 and D3
constitute the major binding site for FGFs and coreceptors.
STD-NMR showed that SSR bound all constructs containing
D2 and/or D3 (Table S1). Figure 1D shows the STD-NMR spectra
of FGFR1 and FGFR4 with SSR. Together with the functional
assays, these data suggest a direct (orthosteric) or indirect
(allosteric) inhibition of FGF binding to ECD of FGFR and/or the
biological function of the receptor.
SSR Inhibits FGF-Induced Signaling and Endocytosis
Pathways
To dissect how SSR interfered with FGFR, we studied its effect
on ERK1/2 activation and FGFR endocytosis. SSR blocked the
FGF2-induced increase in ERK1/2 phosphorylation (Figure 2A)
and translocation of cell surface FGFR4 to the cytosol (Fig-
ure 2B). In addition, SSR inhibited the FGF2-induced intracellular
accumulation of early endosomal antigen1 positive (EEA1+) vesi-
cles, the destination of internalized FGFRs (Figures 2C and 2D).
Similar effects of SSR on FGFR internalization and phosphoryla-
tion of FRS-2 (target of FGFR2) and ERK1/2 were observed in
human gastric SNU-16 cancer cells, in which these processes
rely on FGF7/FGFR2 (Figures 2E and 2F), and in FGFR2-overex-
pressing L6 cells (see below). Blockage of FGFR internalization
could explain the inhibition of FGFR signaling, though other opin-
ions exist (Belleudi et al., 2007; Reilly et al., 2004).
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Figure 2. Effect of SSR on FGFR-Signaling and Endocytosis
(A) Phosphoproteome profiler array of ECs in baseline and response to FGF2 in the presence or absence of SSR (n = 3).
(B) Micrographs of cell surface-localized FGFR to study FGF2-induced internalization of FGFR4with or without SSR (top). Immunoreactive signal for single cells is
quantified in the 2.5D intensity plot (bottom).
(C andD) Staining of FGF2-stimulated ECs for EEA1 in the presence or absence of SSR. Representative images are shown in (C) and quantification result of EEA1+
vesicles is shown in (D, n = 3).
(E) Stimulation of SNU-16 cells with FGF7-alexa488 to study SSR’s effect on endosomal trafficking; SSR119501: inactive SSR-analog (n = 3).
(F) Immunoblotting of SNU-16 cell extracts to study the effect of SSR on FGF7-induced phosphorylation of FGFR2 (p-FGFR), FRS-2 (p-FRS-2), and ERK1/2
(p-ERK1/2). GAPDH: loading control. Scale bars: 50 mm (B); 20 mm (C); 10 mm (E). In (D) and (E): mean ± SEM. The asterisk indicates p < 0.05.
Cancer Cell
Mechanism of SSR to Allosterically Block FGFRsStructural Properties of Extracellular FGFR Domains D2
and D3
To map the interaction site of SSR with FGFR-ECD, we first
generated two-dimensional (2D) 15N-HSQC NMR spectra of
FGFR-ECD in the absence of SSR to obtain the protein’s finger-
print. Peaks in this spectrum correspond to amide groups (and
nitrogen-containing side-chains). Since chemical shift perturba-
tions (CSPs) of these peaks are sensitive to the chemical envi-
ronment, this technique allows identification of SSR interaction
sites with FGFR-ECD.
The spectrum of D2 showed sharp peaks and spectral disper-
sion, as expected for a well-folded domain with defined struc-ture, and all NMR resonances were assigned to a particular
residue. In contrast, the signals of D3 could not be detected,
because they were broadened beyond detection, indicating
that D3 does not adopt a stable, persistent three-dimensional
(3D)-fold (Figures S2A–S2F). This behavior is consistent with
a transiently unfolded flexible state, a phenomenon confirmed
by D30s high tendency to aggregate (data not shown). Because
this behavior can be an inherent property of the domain or,
alternatively, a preparation artifact compromising the analysis
of a potential interaction with SSR, we generated preparations
of functional, structured D3. However, optimization of condi-
tions to solubilize D3, variations of D3 constructs (with/withoutCancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc. 491
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Mechanism of SSR to Allosterically Block FGFRsmembrane or D2D3-Linker), or attachment of solubilizing fusion
constructs (thioredoxin, protein G) all failed to yield spectra
consistent with a stable D3 fold, while the other domains re-
mained readily detectable (Figures S2A–S2D).
Such a very flexible (intrinsically disordered; Tompa, 2011)
state of proteins can be characterized by computer simulations
that estimate the preferred conformational state and stability of
various parts of the protein. We therefore performed multi-ms-
long, unbiased, all-atom, explicit-solvent molecular dynamics
(MD) computer simulations with the Amber99SB*-ILDN force
field. In line with NMR data, D3 was marginally stable and
partially disordered in solution. The Thr319-Arg330 region, which
has an extended b-conformation in the crystal structure, tended
to adopt an a-helical conformation and to detach from the
protein core, leading to partial unfolding of the domain. Plasticity
of this region, in particular of the bC0-bE loop (Pro307-Val332)
plays a key role in the specificity of FGF binding to FGFR splice
variants (Beenken and Mohammadi, 2009). Noteworthy, the
algorithm AGADIR also predicted a propensity for a helix confor-
mation of the Thr319-Arg330 region, thus independently confirm-
ing the MD computer simulations.
To assess if the flexibility of D3 corresponds to a completely
random (random coil) or compact but unfolded (molten globule
[MG]) state and to verify the chemical purity and quality of the
protein used in the NMR experiments, we performed FGFR2-
D2D3 crystallization trials. We resolved a similar structure of
the FGFR2-FGF1 complex, as reported (Plotnikov et al., 1999;
Schlessinger et al., 2000). A defined electron density of D3 re-
vealed a stable structure, suggesting that D3 is only marginally
unstable and ready to fold in conditions of crystallization and/
or upon forces taking place in the crystal. These observations
are compatible with a molten globule state of D3 (in line with
the increased aggregation propensity and disappearance of
NMR peaks). Control experiments showed that the amino acid
composition of the urea-unfolded D2D3 polypeptide chain
was correct (Figures S2E and S2F), that D3 folding was not en-
forced by crystallization conditions (Figures S2G and S2H),
and that D2D3 interactedwith FGF1 (Figures S2Gand S2I). Since
the crystal structure indicates that D2 and D3 are needed to
interact with FGF (Plotnikov et al., 1999; Schlessinger et al.,
2000), these findings show that D3 is present and functional.
Thus, D2 is well folded, while D3 is in an unfolded MG state
that is ready to fold.
Mode of Action of SSR: Effects on D2
We then explored to which sites SSR binds in the FGFR ECD and
used 2DNMR to determine the CSP values upon addition of SSR
to D2 of FGFR1, FGFR2, and FGFR4. SSR-induced CSPs were
mapped on the X-ray structure of FGF2/FGFR1-D2D3/heparin
(Protein Data Bank [PDB] code 1FQ9; Schlessinger et al.,
2000). The CSPs suggested a conserved binding site of SSR in
the vicinity of—but not overlapping with—the heparin binding
site of D2 (red balls show residues interacting with SSR in D2
of FGFRs; Figures 3A and 3B). Chemical shift titration analysis
yielded a binding affinity of SSR to D2 of FGFR1, 2 and 4 in
the mM range (Table S2). These affinities are two to three orders
of magnitude too low to explain the mM SPA data. Moreover, the
computational estimation of the free binding energy of SSR to
FGFR2-D2 (5 kcal/mol) is in line with the mM range of the492 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.observed KD values (Figure 3C). Thus, an interaction of SSR
with D2 alone cannot account for the cellular effects.
We therefore performed binding experiments with FGF/FGFR
complexes. Since NMR signals only appear if the protein is
labeled with 15N isotope, FGFR or FGF was labeled separately
to dissect to which component SSR binds. The effect of
SSR on the 2D NMR spectra of (15N)FGFR2-D2D3/FGF1 and
FGFR1-D1D2D3/(15N)FGF2 is shown in Figure 3D and mapped
on the crystal structure 1FQ9 in Figure 3E. The spatial CSP clus-
tering indicates a binding site for SSR at the interface between
D2 and FGF, in agreement with the binding of SSR to D2 alone.
Confirming STD-NMR experiments that SSR does not bind to
FGF1 or FGF2, SSR induced CSPs in FGF only when a FGF/
FGFR complex was formed. When analyzing the complex
between FGFR1-D1D2D3 and (15N)FGF2, two additional CSPs
were observed: Asn101 (facing D2 in crystal structure 1FQ9)
and Ala57 (facing D3; black circle in Figure 3E, bottom), suggest-
ing an additional binding site for SSR in D3. To evaluate SSR’s
affinity for FGFR/FGF, we performed NMR titration experiments
of FGF1/FGFR1-D1D2D3 with SSR, yielding an affinity constant
in the low mM range (50 mM; Figure 3F). Due to the structural
disorder of D3, a binding mode could not be deduced. Together,
the CSP data indicate a binding site on the interface between
FGF and D2 and a potential binding site on D3. A role for D3 in
SSR binding is supported by the mM affinity of SSR to D2 alone,
too low to explain the biological effect.
Mode of Action of SSR: Low Resolution FGF-FGFR
Crystals
To further assess themolecular basis of the allosteric interaction,
we performed X-ray crystallography. Crystals of FGF1/FGFR2-
D2D3 complexes with SSR could not be optimized to a suitable
diffraction quality, but it was possible to generate crystals with
SR128545 (abbreviated as ‘‘SR’’; Figure S3A), a SSR analog
with comparable cellular activity (Figure S3B). Limited by a
diffraction resolution of 4.2 A˚, the exact binding position of SR
could not be visualized, but conformational protein backbone
changes induced by the interaction with SR were detectable.
Molecular replacement (MR) statistics of Phaser (McCoy et al.,
2007) were used to compare the observed X-ray diffraction
pattern to existing 3D models. This revealed single solutions
without structural clashes when independently using the three
separate domains (FGF1, FGFR2-D2, and FGFR2-D3) of the
FGF1/FGFR2/heparin crystal structure (PDB code 1E0O; Pelle-
grini et al., 2000). These results confirm that the obtained crystal
structures were in agreement with published results (PDB codes
1CVS and 1DJS). We also analyzed the translation function
Z-scores (TFZ), as they are a measure of how well the MRmodel
fits to X-ray data (a high score indicates a good match). TFZ
scores in the presence of SR were smaller for D3 than for D2
or FGF1 (FGF1/SR = 23.1, FGFR2-D2/SR = 15.7, and FGFR2-
D3/SR = 7.5), showing that the structure solution cannot explain
the entire scattering pattern in the presence of SR but rather
suggests a structural change induced by SR.
To confirm the above findings and to determine conforma-
tional dynamics, we refined the structure of the FGFR2-D2D3/
FGF1/heparin/SR complex by generating polyalanine models
using Refmac5 to obtain a model that best explains the experi-
mental data (Murshudov et al., 1996). The electron density of
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Figure 3. 2D-NMR Analysis and Free Energy Profiles
(A and B) Surface representation of FGFR (blue) and FGF (green), showing the SSR binding site in FGFR2 and FGFR4. Amide signals, shifting due to addition of
SSR in 2D 15N-HSQC NMR, were mapped onto the X-ray structure of FGFR1-D2D3/FGF2/heparin mimetic (1FQ9). (A) Highlight of the shifting amide residues of
D2 of FGFR2 and FGFR4, induced by SSR. Red balls indicate residues shifting in both FGFRs (Thr150, Phe170, Arg171, and Cys172; numbering according to
FGFR4). His151 and Arg154 (light blue balls) only shift in FGFR4-D2, and Lys164 (orange ball) is only affected in FGFR2-D2. For both receptors, an identical binding
site of SSRwas observed. For clarity, only onemolecule of FGF and FGFR is shown. (B) For comparison, the binding sites of the saccharide heparin molecules are
depicted in black/gray. The complex with heparin consists of two FGFs and FGFR-D2D3 molecules.
(C) Cartoon representation of themain binding mode of SSR to FGFR2-D2 (fromNMR in this study, yellow; fromMDmodeling, pink) as predicted from free energy
calculations and docking (left), with its corresponding binding free energy profile for SSR, as calculated by metadynamics (right). The low free binding energy
corresponds to the low affinity (mM) of binding, as revealed by NMR studies. Binding of heparin is also shown.
(D) Overlay of the [1H,15N]-TROSY HSQC spectra, revealing CSPs induced by SSR on 15N FGFR2-D2D3/FGF1 (top) and FGFR1-D1D2D3/15N FGF2 (bottom);
SSR-induced CSPs are indicated by arrows: black without SSR and red with SSR.
(E) CSPs induced by SSR in the experiments shown in (D) weremapped to the X-ray structure (1FQ9). Red balls denote residues showing CSP. Only onemolecule
of FGF and FGFR is shown.
(F) NMR titration experiments of the FGF1/FGFR1-D1D2D3 complex with SSR. Top: 1H 1D signal of the SSRmethoxy resonance. Black lines show themeasured
spectra; red lines indicate a least square fit using full signal simulation (performed by variation of KD and koff). Bottom: Chemical shift of the peak maximum (x axis)
as a function of the ratio of complex to SSR concentration. Asterisks show the experimental values; the solid line results from a least square fit of the chemical shift
data by variation of the reaction parameters.
See also Figure S2 and Table S2.
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Mechanism of SSR to Allosterically Block FGFRsall domains was fully recovered by molecular replacement after
separate deletion of single domains in the PDB file. In the
presence of SR, the density of FGFR2-D3 was weak around
a b sheet region (b2 at Asp272-Val277 and b5 at Glu325-Ile329)
located 25 A˚ away from the orthosteric FGF-ligand-binding
region in D3. Comparison of FGFR2-D2D3/FGF1 structures in
the absence and presence of SR revealed no conformationaldifferences. However, strong differences in the Debye-Waller
factors (B-factors; higher values suggest flexibility) were
observed. Surprisingly, the average B-factor of the X-ray protein
structure in the presence of SR was strongly increased. Specific
regions in FGFR2-D3 at b1b2 (Ala266-Val277) and a1b5 (Thr319-
Ile324Glu325-Ile329) showed large decreases in the occupancy
of atoms, resulting in high B-factors (Figure 4A). Together,Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc. 493
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Figure 4. Crystallography, FTIR Analysis, and
Free Energy Calculations
(A) 3D representation of the X-ray crystal structure of
FGFR2-D2D3/FGF1 complex in the absence (left)
and presence (right) of SR. The change in colors
(B-factor values) suggests increased flexibility of D3
at a1/b5 after SR binding.
(B) FTIR measurements of FGFR2-D23WT and
FGFR2-D23Y328D in the absence (blue) or presence
(red) of SSR.
(C) Calculated free energy surfaces as a function of
the b sheet and a helix content (nb and na, respec-
tively; see Supplemental Information) in the absence
(left) or presence (right) of SSR. The native state is
marked with ‘‘N’’. Note the appearance of a new free
energy minimum corresponding to the H2 state.
See also Figure S3.
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Mechanism of SSR to Allosterically Block FGFRsthe conformation of the FGF-FGFR complex and flexibility of
FGFR2-D2 or FGF1 were not strongly affected by SR. However,
TFZ scores, disturbed electron density maps, and increased
B-factors suggest increased structural dynamics of D3, resulting
from different conformational states induced by SR.494 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.Mode of Action of SSR: Effect of SSR
on FGFR-D3
The finding of an intrinsically disordered D3
domain in NMR studies andMD simulations
together with the SR-induced increase of its
B-factors in the X-ray structure led us to
further investigate the influence of SSR on
D3 using Fourier transform infrared (FTIR)
spectroscopy and in silico methods. By ob-
taining an infrared spectrum of absorption,
FTIR provides information on the transition
from one to another conformation. Addition
of SSR to FGFR2-D2D3 increased the
amplitude of the amide I band in the FTIR
spectrum with a maximum at 1,640 cm1
(Figure 4B), suggesting that binding of
SSR leads to a conformational change of
FGFR-D2D3 (similar results were obtained
when analyzing FGFR2-D1D2D3), in agree-
ment with the AGADIR prediction.
We used state-of-the-art free energy (DG)
calculations and computer modeling to
unravel how the conformational landscape
and flexibility of D3 changed in the presence
of SSR. The free energy calculations were
performed with the Gromacs 4 package
and PLUMED plug-in using metadynamics,
bias exchange metadynamics, and steered
MD approaches and the Amber99SB*-ILDN
force-field (Best and Hummer, 2009; Piana
and Laio, 2007). Similar techniques were
used previously to predict the free energy
landscapes associated with conformational
changes and ligand binding in kinases
(Lovera et al., 2012; Saladino et al., 2012).
Comparison of the free energy landscapesof D3 as a function of the b sheet and a helix content predicted
that SSR stabilizes helix a1 (Thr319-Ile324) and induces a b sheet
to a helix transition of part of b5 (Gln325-Ile329), thereby nearly
doubling the number of turns in helix a1. As a result, D3
undergoes a conformational rearrangement into an intermediate
Cancer Cell
Mechanism of SSR to Allosterically Block FGFRs‘‘H1’’ state, which progresses to state ‘‘H2,’’ where a new hydro-
phobic cavity, not accessible in the native form of D3, is formed,
in which the hydrophobic Tyr328 residue (solvent exposed in the
native configuration) now faces the core of D3 (Figures 4C and
S3C). The difference in free energy between the crystallo-
graphic fold of D3 and the refolded H2 state, calculated by two
independent approaches (bias exchange metadynamics and
steered MD simulations) was 2 to 3 kcal/mol. These data, in
agreement with NMR and X-ray observations, suggest that D3
binds SSR and undergoes conformational rearrangements
without becoming fully structured in the SSR-bound state.
Mode of Action of SSR: Helix-Breaker Mutations
To assess the importance of Tyr328 in the conformational
changes of FGFR-D3, we mutated this residue to aspartate,
which has known ‘‘helix-breaker’’ properties (to yield FGFR2-
D2D3Y328D, termed FGFR2Y328D), as this mutation should reduce
the helical tendency and impair the conformational change.
Indeed, we hypothesized that the hydrophilic Asp328 would
destabilize the a-helical conformation and that SSR would not
be able to induce a conformational change in FGFR2Y328D.
FTIR revealed that FGFR2Y328D did not exhibit a major shift in
its spectrum in the absence of SSR, showing that its overall 3D
configuration was preserved. Conformational analysis by FTIR
showed, however, that SSR failed to induce a change in the
spectrum of FGFR2Y328D (Figure 4B). This effect was specific,
as additional mutations of the Y328 residue (Y328R/I329K) still
showed the same structural change as FGFR2WT upon addition
of SSR, illustrating that not any type of mutation of Y328 per se
could rescue the SSR effects (data not shown).
The aforementioned observations suggest that SSR does not
directly compete with FGF binding, but rather that it alters the
conformational ensemble of FGFR-ECD, which allosterically
propagates into receptor function changes. The b to a transition
of the b5 helix (Glu325-Ile329) is critically involved in this allosteric
effect. To assess the relevance of Tyr328 in transmitting SSR’s
allosteric activity, we generated HEK293 cell lines expressing
wild-type FGFR2WT or mutant FGFR2Y328D. In the absence of
SSR, FGFR2WT and FGFR2Y328D cells exhibited a similar
ERK1/2 response to FGF2, showing that the mutation did not
change FGFR’s response to FGF. The mutation did also not alter
orthosteric binding of 125I-FGF2 (KD: 54 ± 8 pM for FGFR2
WT
versus 52 ± 9 pM for FGFR2Y328D; n = 5; p = NS). However,
SSR’s ability to inhibit FGF2-induced ERK1/2 phosphorylation
was reduced in FGFR2Y328D cells (IC50 value: 121 ± 30 nM) as
compared to FGFR2WT cells (IC50 value: 28 ± 12 nM; p < 0.05)
(Figures 5A and 5B). Similar data were obtained for FGFR2 phos-
phorylation and phospho-FRS2 signaling (Figures 5C and 5D).
We also stably overexpressed FGFR2WT or FGFR2Y328D in L6
myoblast cells (which lack endogenous FGFRs). Transduced
cells were treated with AlexaFluor488-conjugated FGF2, leading
to the formation of FGF2/FGFR2 at the cell membrane and its
internalization in endocytic vesicles. Upon stimulation, FGFR2WT
and FGFR2Y328D were comparably endocytosed (Figures 5E and
5F). Notably, SSR reduced endocytosis in FGFR2WT but not in
FGFR2Y328D cells (Figures 5E and 5F). To unravel the endocytic
pathway, inhibitors of clathrin- (Pitstop2) and caveolin-depen-
dent (Dyngo-4a) pathways were used. Only Dyngo-4a affected
endocytosis of FGFR2WT and FGFR2Y328D, indicating that theFGF2 endocytic pathway relies on caveolae-dependent internal-
ization (Figures 5E and 5F), consistent with previous reports
(Irschick et al., 2013). Thus, FGFR2WT and FGFR2Y328D showed
similar profiles with respect to FGF2 affinity, ERK1/2 phosphor-
ylation, and receptor internalization, but SSR inhibited signaling
more efficiently in FGFR2WT than FGFR2Y328D cells. Thus, by
altering the b to a transition of the b5 strand and thereby elon-
gating the a1 helix, SSR modulates inhibition of FGFR signaling
and internalization.
Mode of Action of SSR: Binding of SSR to D3 H2
Because of the flexibility in D3, we performed in silico binding
studies using metadynamics, a recently developed method to
dock ligands on receptors in water solution, allowing protein
flexibility (Laio and Gervasio, 2008). This revealed that the free
energy of binding to the hydrophobic cavity in the H2 state
was 10.2 kcal/mol (Figure 6A), reflecting tight binding in the
nM range. Overall, very long all-atom MD simulations and free
energy calculations with metadynamics confirmed that SSR
alters the flexibility and conformational propensity of D3. The
stability of the helical region in FGFR2-D3 is enhanced by an
initial step of low-affinity SSR binding, thereby making a new
metastable H2 state accessible, which is stabilized by docking
of SSR (Figures 6B–6D and S3C). Superposing D30s structure
in its SSR-boundH2 state with previously identified crystal struc-
ture of FGFR2-D2D3 showed that the FGF-interacting residues
remain unaffected, in line with findings that SSR did not alter
the affinity of FGFs.
In addition, free energy calculations showed that FGFR2Y328D
underwent helix elongation and adopted the conformational
state H2, though H2 was less stable. This relates to the fact
that stabilization of the cavity is largely due to interactions of
the hydrophobic Tyr328 with the core of D3 and that these inter-
actions are highly unfavorable in FGFR2-D3Y328D, in which the
hydrophilic Asp328 prefers solvent exposure rather than buried
conformations. Our finding that Y328D reduces but does not
eliminate SSR binding explains why FGFR2Y328D is still capable
of binding SSR but also why its signaling is inhibited less by SSR.
Structure-Activity Relationship Analysis
Experimental and computational approaches suggest a noncon-
ventional allosteric regulation of FGFR function by binding of
SSR to the disordered ensemble of D3. MD simulations outline
the major structural features of the H2 state and schematic
features of the arising binding cavity. To further probe themolec-
ular details of the D3-SSR interaction, we analyzed the structure
activity relationship (SAR) of a set of 19 SSR analogs by com-
paring their biological activity (inhibition of phospho-ERK1/2
signaling) to their capacity to dock into the in silico-identified
binding pocket of D3 (H2 state) using the Schro¨dinger Glide XP
package on the nonflexible H2 state of FGFR2-D3. As shown
in Table S3, two active SSR analogs inhibited ERK1/2 phosphor-
ylation with a comparable efficiency as SSR (IC50 10–100 nM);
their activity was reduced in FGFR2Y328D cells (Table S4), con-
firming the specificity of their activity. Six other compounds
had weak biological activity (IC50  100–1,000 nM), while
another tenmolecules were inactive (IC50 > 1,000 nM). One com-
pound could not be tested because of insolubility. Docking ex-
periments showed that the binding energy generally correlatedCancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc. 495
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Figure 5. FGFR Signaling in FGFR2WT and
FGFR2Y328D Cells
(A–D) Analysis of inhibition of FGFR2WT or
FGFR2Y328D by SSR in HEK293 cells stably ex-
pressing these proteins using immunoblot. Phos-
phorylated ERK1/2 (pERK1/2) and total ERK1/2
(ERK1/2), upon FGF2 stimulation, were determined
and ratios of pERK1/2 over total ERK1/2 were used to
calculate IC50 values (A and B; mean ± SEM, n = 3).
The asterisk indicates p < 0.05 versus FGFR2WT.
FGFR2 was used as loading control. Similar results
were obtained when analyzing phosphorylation of
FGFR2 (C) and FRS2 (D) upon prior immunoprecipi-
tation for phosphotyrosine (pTyr) residues (the ratio of
phospho- over total protein is shown).
(E and F) Analysis of endocytic vesicle formation
in L6 myoblasts stably expressing FGFR2WT or
FGFR2Y328D and stimulated with AlexaFluor488-
conjugated FGF2 in the presence of control, SSR
(1 mM), Dyngo-4a (3 mM, DYN), or Pitstop2 (1 mM, PS).
Representative images are shown in (E) (scale bars:
20 mm), and the result of quantification of the number
of AlexaFluor488-conjugated FGF2 endocytic vesi-
cles is shown in (F). Each bar corresponds to the
number of vesicles detected on 28–30 views from
three different wells (mean ± SEM; n = 3). The asterisk
indicates p < 0.05 versus FGF2 alone.
Cancer Cell
Mechanism of SSR to Allosterically Block FGFRswith biological inhibition and that the binding strength of the
active compounds was significantly higher than of the weak
and inactive compounds (Figure S4A).
Computational modeling suggested that several critical
substitutes were adjacent to residues in the Thr319-Arg330 region
(i.e., R1 and R2 in the vicinity of Leu327-Tyr328-Ile329 and R0
and R00 pointing toward Thr319-Thr320-Glu323-Ile324; Figure 7A).
More detailed analysis revealed the following insights (Table
S3): (1) R0 group: a carboxylate group (or amide bioisostere) at
R0 is required for full biological activity (compound 7); changing
this group abrogated SSR’s activity (compounds 10–13,16);496 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.switching the carboxyl group at R0 and the
aniline group at R00 retains residual activity
(compound 5), likely because of sufficient
docking, but this configuration is less favor-
able because one charge-charge interac-
tion (with Lys279) and a H-bond between
neutral groups (Thr319, Thr320) are replaced
with H-bond interactions between charged
and neutral groups; (2) R00 group: the aniline
group is required as its removal (compound
4 and 17) or monomethylation (compound 6)
lowered the activity, in line with the observa-
tion that these compounds had reduced
polar and H-bond interactions in the H2
state; (3) R1 group: switching the methoxy
group for a carboxyl group prevents dock-
ing into the H2 pocket (compound 11), but
this group can be replaced by a hydrogen
atom without losing activity (compound 3),
highlighting the need for hydrophobic
interactions not compatible with negativecharge; and (4) R2 group: the methyl group can be substituted
by a cyclopropyl group, retaining potency consistent with com-
parable hydrophobic interactions with the pocket (compound 2).
These data confirm that the Thr319-Arg330 region is important
for SSR binding and transduction of the allosteric information.
Noteworthy, the R1 moiety facing Tyr328 is critical, explaining
why SSR binding and inhibitory activity were impaired by the
bulky methoxybenzamide and methoxybenzenesulfonamide
at R1 (compounds 17 and 18). Likewise, the bulky CONHMe
at R6 (compound 8) is not tolerated, probably because of
steric clashes with the hydrophobic pocket. Other substitutions
A B
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Figure 6. Free Energy Calculations and
Conformational States
(A) Cartoon representation of the main binding
mode of SSR to FGFR2-D3, as predicted from free
energy calculations and docking (left) and the
corresponding binding free energy profile for SSR
as calculated by metadynamics (right).
(B–D) Cartoon representation of the conformation
adopted by FGFR2-D3 in the native state (without
SSR) (B) and in the H2 state in the presence of SSR
(C), as obtained by calculating the free energy
using molecular dynamics modeling (for reasons
of clarity, SSR itself is not shown); the overlay is
shown in (D). Note the elongated helix a1 and the
position of Tyr328 pointing toward the hydrophobic
core of the domain in the H2 state compared
to the native state. FGF1, green; native FGFR2-
D3, blue; FGFR2-D3 ‘‘H2’’ conformation, gray;
helix a1, red.
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with binding itself, which is compatible with the allosteric mode
of action, in a sense that not binding per se but rather the confor-
mational change induced by the SSR derivative matters.
On a subset of active, weak, and inactive compounds (Table 1),
we performed biophysical (STD-NMR and waterLOGSY-NMR;
Bretonnet et al., 2007) experiments to assess their binding
capacity to FGF1/FGFR2-D2D3. Also, to allow flexibility of
protein movements, we calculated the free binding energy (DG)
of these compounds using metadynamics, which, in contrast to
standard modeling on a rigid structure, also takes into account
movements of the protein. The agreement between the calcu-
lated DG and biological activity is superior to that obtained with
the Glide XP score (Table 1; Figures 7B and S4B). For instance,
when we subtract the thermodynamic penalty of state H2
(2 to 3 kcal/mol) from the calculated binding free energies, we ob-
tained 8/9 and 9/10 kcal/mol for SSR and compound 2,
which is in very close agreement with the expected value of
8.5 kcal/mol for compounds in the 100 nM affinity range. An
agreement is also obtained for weak and inactive compounds.
The superior agreement of the free energy (calculated by Meta-
dynamics) over the docking scores (calculated by Glide XP)
stresses the importance of considering flexibility and explicit
water hydration.
This view is also supported by NMR measurements, in which
STD and waterLOGSY NMR were used to rank binding of this
subset of compounds (Table 1). The NMR data are in good
agreement with the calculated binding energy values and bio-Cancer Cell 23, 489–5logical potency. Two compounds from
the active group bound the strongest,
and SSR itself was the third strongest
binder, which also underscores that,
besides binding strength itself, the
compatibility with the structural allosteric
transition is also important for the effect
of the compound. Again, adding large
groups at R1 induces the most profound
effect (compound 17 being the weakest
and compound 18 being undetectableby NMR due to protein precipitation). Overall, the binding
affinity of SSR variants and their allosteric effect of binding
generally correlate: the stronger a derivative binds, the more it
drives the conformation of the receptor toward the inhibited
ensemble.
DISCUSSION
In the accompanying paper (Bono et al., 2013), we identified
SSR, a synthetic inhibitor of the FGF tyrosine kinase receptor,
and provided pharmacological evidence for an allosteric mech-
anism. This orally deliverable, small-molecule, multi-FGFR inhib-
itor showed promising therapeutic anticancer efficacy (Bono
et al., 2013). SSR does not affect orthosteric FGF ligand binding,
cannot penetrate the membrane, and does not directly block the
TK activity but exhibits typical pharmacological allosteric fea-
tures. Indeed, the compound shows signaling bias by inhibiting
ERK1/2 activation (relying on FGFR internalization) without alter-
ing phospholipase C (PLC)-g phosphorylation, has a ‘‘ceiling’’
effect, and exhibits ‘‘probe dependence’’ (Bono et al., 2013).
All these findings suggest an allosteric conformational effect
that discriminatively affects the readout of receptor activation.
In this study, efforts were made to unravel the molecular mech-
anisms of the allosteric activity of SSR. The challenge in these
investigations is due to both the complexity of the FGFRs and
the disordered, even unfolded nature of domain D3, which is
prone to aggregation, invisible to NMR, and highly flexible in
the X-ray structures in the presence of SSR.01, April 15, 2013 ª2013 Elsevier Inc. 497
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Figure 7. SAR and Hypothetical Model of the Allosteric Regulation of FGFR by SSR
(A) Scheme of the putative SSR binding pocket in the newly exposed cavity in the H2 state, used for the docking analysis to obtain the SAR. The position and type
of individual amino acid residues and putative interactions are indicated. The colored band lining the cavity represents hydrophobicity (green is hydrophobic; blue
is charged).
(B) Scatterplot analysis of calculated binding energy using metadynamics of the three different classes of compounds from the SAR analysis. The compounds of
each group are shown in Table 1. The asterisk indicates p < 0.05 between the indicated conditions (dashed lines); horizontal full lines represent averages.
(C) Under normal conditions, heparin sulfate-bound FGF (orange circle) binds to FGFR ECD via D2 (green) and D3 (red). While D2 is well folded, D3 is in
a disordered native (N, probably corresponding to amolten globule) state. The receptor can dimerize and induce distinct intracellular signaling pathways, such as
receptor internalization (leading to ERK1/2 phosphorylation) and PLC-g phosphorylation. Due to its inherent flexibility, D3 can transit to an alternative disordered
state (H1), which is more open and competent for weak SSR binding. From this state, there is a transition to a third disordered state (H2), which binds SSR
stronger. In this state, SSR does not inhibit FGF binding or dimerization, but, due to altering the conformational ensemble and/or dynamics of D3, it inhibits
receptor internalization. Allostery of the system arises from SSR acting indirectly via long-range conformational effects in the disordered ensemble, attenuating
membrane interaction.
See also Figure S4 and Tables S3 and S4.
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Mechanism of SSR to Allosterically Block FGFRsAt first, it may appear surprising that a small molecule like SSR
is capable of inhibiting the responses of various FGFRs to
multiple FGF ligands if steric hindrance of the orthosteric FGFR
pocket was the desired mode of receptor targeting. However,
an allosteric interaction with a small molecule can perturb the
signaling of a large FGF ligand by inducing a conformational
change in FGFR. The model that emerges from computer simu-
lations and modeling reconciles the experimental findings by
predicting a marginally stable D3 fold, a weak SSR binding site
on D2, and a conformational change in D3 in the presence of
SSR. The AGADIR software also independently predicted
a conformational preference of a helix over b sheet structure.
The conformational change gives rise to a new hydrophobic
cavity, to which SSR can bind. A mutation that reduced the
a-helical propensity in this region was predicted to suppress
the SSR-induced conformational changes in silico and indeed
counteracted SSR’s ability to inhibit FGFR-driven cellular
processes.
The key element of the model is the allosteric nature of SSR’s
action. Whereas this molecule was selected by using the SPA
assay for FGF binding and has nM pharmacological effects, it
does not interfere with FGF binding or receptor dimerization in
a cellular context. Because SSR is not internalized, it acts on
the extracellular part of the receptor. Direct SSR binding to
FGFR was indeed demonstrated experimentally, as was the
conformational change that is critical for affecting receptor func-
tion. Allostery also follows from the ‘‘ceiling’’ effect, the differen-498 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.tial effect on distinct downstream signaling pathways, and
‘‘probe dependence’’ (Bono et al., 2013). All these observations
can be reconciled with data from structural experiments and
modeling calculations in the followingmodel: (1) an SSR-induced
conformational rearrangement of D3 is suggested by most tech-
niques; (2) structural disorder of D3 is confirmed by NMR, MD
simulations, and high-crystallographic B-factors; and (3) defec-
tive receptor internalization in the presence of SSR is shown in
cellular assays and suggested by differential pharmacological
effects.
Therefore, the structural underpinning of the system is that the
actual structural state of domain D3 is probably a conformational
ensemble corresponding to a MG state, with a global topology
resembling the structure stabilized in crystallography. This
domain thus falls into the growing family of intrinsically disor-
dered proteins, which lack well-defined stable folds, yet play
key regulatory and signaling roles in many cellular processes
(Tompa, 2011). Its dimerization, even without a folding transition,
can be envisaged, as in fuzzy complexes (Tompa and Fuxreiter,
2008) such as T-cell receptor zeta (Duchardt et al., 2007; Sigalov
et al., 2004). As is the case with MG states, its various conforma-
tions are in an intermediate kinetic exchange regime that causes
severe line broadening in NMR, making it invisible to the NMR
(Park et al., 2011).
The native ensemble of D3 samples the minor state H1, in
which the b5 region tends to adopt local helical conforma-
tions; this structural state is stabilized by weak interactions
Table 1. Structure Activity Relationship of SSR Analogs
Compound R1
a R2 R
0 R00
pERK Inhibition
(IC50 Range, nM)
b
DG of Binding
(calculated, kcal/mol)
Glide XP
Score
NMR Binding
Event (fSTD/fWL)
Active
1 (SSR) OMe Me COOH NH2 <100 11 10.3 2.0/3.8
2 OMe cPr COOH NH2 <100 12 11.3 4.9/15.0
3 H Me COOH NH2 <100 10c 11.3 4.4/12.6
Weak
5 OMe Me NH2 COOH <1,000 8 8.2 1.5/3.2
6 OMe Me COOH NHMe <1,000 9 9.8 3.8/11.6
7 OMe Me CONH2 NH2 <1,000 9 9.1 ND
9 Et Me COOH NH2 <1,000 8 12 ND
Inactive
13 OMe Me COOMe NH2 >1,000 8 10.3 ND
14 OMe Me COOH OH >1,000 5 11.9 ND
17 3-Methoxybenzamide Me COOH H >1,000 4 4.7 0.7/1.9
18 3-Methoxybenzene-sulfonamide Me COOH NH2 >1,000 ND 4.2 Not detectable
Compound 1 is SSR. ND, not determined; fSTD, STD amplification factor; fWL, quantitative waterLOGSY effect.
See also Tables S3 and S4.
aThe position of the groups (R0, R00, R1, R2) is indicated in the chemical structure in Figure 7A.
bThe inhibition of ERK1/2 phosphorylation was determined for four concentrations of each compound (i.e., 1, 10, 100, and 1,000 nM).
cA major induced fit effect on D3 is observed, increasing the uncertainty on this estimate.
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Mechanism of SSR to Allosterically Block FGFRswith SSR, as indicated by an increase of B-factors upon
SR binding, MD simulations, and FTIR. Local helical conforma-
tions are also underlined by AGADIR predictions. Overall, this
transition is compatible with the ability of small molecules to
bind to the disordered state, as observed in the inhibition of
Myc-Max heterodimerization (Metallo, 2010). The SSR-FGFR
interaction is likely heterogeneous, as suggested by the failure
of observing electron density for the bound SR in the crystal
structure.
MD simulations suggest that, upon transition to this transient
and heterogeneous complex, a hydrophobic cavity becomes
exposed, in which Tyr328 plays a key role. This transient complex
may then relax into a more stable structural ensemble (H2), in
which SSR is buried in the hydrophobic cavity (Figure S3C).
This results in amuch stronger interaction, which does not inhibit
FGF binding but alters FGFR signaling, possibly due to inter-
fering with membrane binding and/or internalization (Figure 7C).
Disorder of this state is confirmed by increased crystallographic
B-factors in the SR-complex and MD simulations and is also
compatible with the allosteric nature of regulation of the re-
ceptor. Transitions in the ensemble N / H1 / H2 translate
into different interactions with the membrane and/or different
dynamics and orientations of receptor subunits in the dimer, re-
sulting in inhibition of receptor internalization but not PLC-g
phosphorylation. In all, this scenario is fully compatible with
recent concepts of allostery, which emphasize the importance
of changes in dynamics without alteration of the equilibrium
conformation (Tzeng and Kalodimos, 2009), and/or redistribution
of the ensemble of intrinsically disordered protein structures
(Hilser and Thompson, 2007). The outcome of these transitions,
as seen in in cellulo assays, is an inhibition of slow and irrevers-
ible FGF-dependent receptor endocytosis abolishing ERK1/2
phosphorylation. A similar allosteric mechanism was describedfor the ganglioside GM3 and EGF receptor; the latter is closely
related to FGFR (Coskun et al., 2011).
The allosteric effect was also confirmed by SAR analysis,
which shows a good correlation of binding free energies of
various SSR derivatives and their allosteric inhibition calculated
by metadynamics modeling, while the docking scores, with their
known limitations, also have an overall correlation with biological
activity. This behavior would be fully incompatible with an
orthosteric competitive inhibition of FGF binding and can be
best explained by a binding model in which the allosteric activity
of the compound stems from its ability to induce the proper shift
in the conformational ensemble of the receptor. In most cases,
altering substituent R1, which faces Tyr328, impairs the allosteric
activity of the compound, which points to the importance of this
residue in the allosteric transitions.
Mutagenesis studies of Tyr328 are also in line with this conclu-
sion, because the Tyr to Asp replacement does not basically
affect the D3 structural ensemble, leaving its FGF-binding
capacity and dimerization intact. On the other hand, it reduces
the capacity of the structure to sample the local helical confor-
mations, characteristic of H1 (and H2) states, thus altering SSR
binding and its ability to interfere with signaling. This is in line
with our FTIR experiments, MD simulations, and cellular assays.
In addition, this disorder-based binding and allosteric mecha-
nism is also compatible with the relaxed specificity of SSR,
which is capable of interfering with different FGFR variants in
distinct species. This would be difficult to reconcile with a well-
folded (preformed) binding cavity on D3, which would limit
FGFR isoform specificity toward SSR. Adaptability of the struc-
tural ensemble of intrinsically disordered proteins in binding is
observed in many cases (Dunker et al., 2008). A corollary of
this conserved allosteric regulation in all FGFR structures is
that the receptor may have endogenous regulatory compound(s)Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc. 499
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open exciting avenues of FGFR research.
A final word is due on the difference of Ki values observed in
the distinct in vitro and in vivo experiments. Such an enhanced
response to small-molecule effectors in vivo is often observed
(Hanoulle et al., 2007; Huppa et al., 2010), probably due to
cellular conditions, such as the presence of additional (protein)
factors or the vicinity of the membrane. The latter is probably
signaled by the preferential inhibitory effect on receptor internal-
ization rather than PLC-g phosphorylation. In the case of FGFR,
this effect may be augmented by the structural sensitivity of the
conformational ensemble of the D3 domain.
What are the possible implications of this study? From a
structural biology perspective, our study provides insight in
fundamental mechanisms of how FGFRs transmit signals and
provides unprecedented evidence for allosteric regulation of
growth factor receptor tyrosine kinases. We show the impor-
tance of taking into account target flexibility in order to under-
stand the mode of action of allosteric ligands. In addition, from
a biopharmaceutical perspective, our results unveil the thera-
peutic potential for FGFR antagonists, perhaps wider than previ-
ously attributed to tyrosine kinase inhibitors, since SSR blocks
not one but multiple FGFRs and because allosteric modulators
are considered to have an improved benefit/risk ratio and to offer
opportunities for fine-tuning biological responses in a manner
that is not attainable with classic orthosteric modulators (Chris-
topoulos, 2002). Finally, our results show that development of
orally deliverable selective allosteric inhibitors of growth factor
receptors is feasible, which creates formidable therapeutic
opportunities for the future.
EXPERIMENTAL PROCEDURES
Compound Reconstitution
SSR was stored as pure powder at 4C in the dark. For the different assays,
SSR was dissolved in DMSO at a concentration of 100 mM and stored at
20C until further use. SU5402 (Calbiochem) was also dissolved in DMSO
at a concentration of 10 mM and stored at 20C. For each assay, the same
amount of DMSO was used for the control condition.
Materials
FGF1 and FGF7 were purchased from R&D Systems and FGF2 was produced
and purified in-house. Human umbilical vein endothelial cells (HUVECs) are
single-donor HUVECs from Promocell.
Cell Survival
Apoptotic cells were detected using fluorescein isothiocyanate-conjugated
annexin V. Each assay was performed in triplicate and repeated three times.
FGFR2 Kinase Assay
Kinase activity measurements of the recombinant catalytic domain of FGFR2
was done using the ADP-Glo Kinase Assay and the Cyclex FGFR2 Kinase
Assay/ Inhibitor screening kit (Sanbio, Uden, The Netherlands) according to
the manufacturer’s protocol.
Confocal Microscopy Studies
EEA-1 labeling was performed on HUVECs or SNU-16 cells starved for 24 hr in
1% fetal bovine serum containing medium and stimulated for 2 hr with FGFs
diluted in prewarmed medium without fetal calf serum in the presence or
absence of SSR. Cells were then rinsed with cold PBS and fixed for 15 min
with paraformaldehyde 4% and then permeabilized with PBS-Triton 0.1%
for 5 min. Following washing with cold PBS, nonspecific sites were saturated
with 1% normal goat serum (Zymed) in PBS for 1 hr at room temperature.500 Cancer Cell 23, 489–501, April 15, 2013 ª2013 Elsevier Inc.Early endosomal vesicles were detected using mouse anti-human EEA1
antibody (1/100, BD Biosciences) overnight at 4C and revealed with
AlexaFluor488-conjugated anti-mouse antibody (1/2,000, Invitrogen) for 2 hr
at 4C. Wells were rinsed twice with 1 ml PBS. Then, all liquids were removed
and one drop of Fluoprep (Biomerieux) was added and mounted with a round
coverslip (KnittelGla¨ser). Confocal microscopy views were performed with
a Zeiss LSM510. The number of EEA1-positive vesicles around the nucleus
was counted with Columbus software (PekinElmer). For FGF-R4 staining,
HUVECwere only fixedwith DakoCytomaton kit following supplier recommen-
dations. FGF-R4 was detected with primary anti-FGFR4 MAB685 (1/100, R&D
Systems).
Western Blot Analysis and Phosphoproteome Profiler Array
These studies were realized on 24 hr-starved cells that were then stimulated
for 7 min with FGFs in the presence or absence of SSR. Immunoblots were
carried out with anti-phosphoprotein antibodies against FGFRs (Santacruz
Biotech, Sc30262), FRS2 (Cell Signaling Tech., 3864), Erk1/2 (Cell Signaling
Tech., 4377), or anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Cell Signaling Tech., 2118). The proteome array was run in accordance with
supplier recommendations.
FTIR Measurements
FTIR was performed using a Bruker Tensor 37 FTIR spectrometer equipped
with an AquaSpec flow cell. The sample compartment was thermostatted to
25C and 100 spectra were averaged for a good signal-to-noise ratio. Proteins
were purified as described in Supplemental Experimental Procedures. Imme-
diately after the gel filtration, the proteins were dialyzed overnight in the same
preparation of buffer (10 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic
acid pH 7.2, 150 mM NaCl) in the presence or absence of SSR. Dialysis buffer
samples were used to subtract background signal. The analysis was per-
formed using the OPUS software package provided by Bruker.
STD- and 1D-NMR Measurements
All STD- and 1D-NMR experiments were carried out on a BRUKER three-
channel DRX600 and on a BRUKER four-channel DRX800 spectrometer at
the standard temperature of 298 K and were referenced to the internal
standard 3-trimethyl-2,2,3,3-tetradeuteropropionate sodium salt. A detailed
description has been included in the Supplemental Information.
X-Ray Crystallography
Crystals of FGF1/FGFR2 D2D3 complexes with and without SR/SSR com-
pounds could be obtained under crystallization conditions containing 0.1 M
Tris/HCl pH 8, 1.8 M (NH4)2SO4 at protein concentration of 2 mg/ml. Crystals
with SSRdiffracted up to 6 A˚, whereas SRbound crystals diffracted up to 4 A˚ at
SLS Villingen. Data could be integrated using XDS and phased with Phaser,
using MR of separate domains FGF1, FGFR2 D2, and FGFR2 D3 of the crystal
structure 1E0O. Because of bad resolution, all residues were mutated to
alanine. The poly-A backbone model of FGF1/FGFR2 D2D3 was refined using
Refmac5 and Coot.
In Silico Molecular Modeling and Metadynamics Modeling
All the detailed procedures are in the Supplemental Information.
Other Assays
For methods such as cell proliferation, survival, FGFR kinase assay, confocal
microscopy, FTIR, and western blotting, we used standard protocols that are
detailed in the Supplemental Experimental Procedures.
Statistics
All data represent the mean ± SEM of the indicated number of experiments.
Statistical significance was calculated by Student’s t test, considering
p < 0.05 as statistically significant.
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